Prostate cancer incidence rates in the United States vary significantly across racial and ethnic groups, with Non-Hispanic Black men facing the highest risk. According to recent data, Non-Hispanic Black males have an incidence rate of 194.8 per 100,000 population, which is substantially higher than the overall rate of 120.2 per 100,000. This stark disparity highlights the importance of targeted screening and prevention efforts to address this health inequality. Incidence and mortality trends The burden of prostate cancer in the U.S. has grown in recent years. In 2025, approximately 313,780 men were projected to be diagnosed with prostate cancer, representing a significant increase from previous years. Despite this rising incidence, mortality rates have shown improvement. In 2022, the prostate cancer death rate was 18.7 per 100,000 men, compared to a rate of almost 39 per 100,000 in the year 1990. This decrease reflects advancements in treatment and early detection. Risk factors and survival rates Age remains a critical risk factor for prostate cancer, with men aged 65 to 84 having a 10.6 percent chance of developing the disease. However, there is encouraging news regarding survival rates. From 2014 to 2020, the five-year relative survival rate for prostate cancer patients in the U.S. was an impressive 97 percent. This high survival rate underscores the importance of early detection and the effectiveness of current treatment options.

This statistic shows the rate of registrations of newly diagnosed cases of prostate cancer per 100,000 population in England in 2020, by region. With a rate of 160.2 newly diagnosed males with prostate cancer per 100,000 population in 2020, the region most affected by prostate cancer was South East.

Background: Knowledge on missing data in a clinical cancer register is important to assess the validity of research results. For analysis of prostate cancer (Pca), risk category, a composite variable based on serum levels of prostate specific antigen (PSA), stage, and Gleason score, is crucial for treatment decisions and a strong determinant of outcome. The aim of this study was to assess the proportion and characteristics of men in the National Prostate Cancer Register (NPCR) of Sweden with unknown risk category. Material and methods: Men diagnosed with Pca between 1998 and 2012 registered in NPCR with known or unknown risk category were compared with respect to age, socioeconomic factors, comorbidity, cancer characteristics, cancer treatment, and mortality from Pca and other causes. Results: In total, 3315 of 129 391 (3%) men had unknown risk category. Compared to other men in NPCR, these men more often had a concomitant bladder cancer diagnosis, 19% versus 1%, diagnosis of benign prostatic hyperplasia 31% versus 5%, received unspecified Pca treatment 16% versus 3%, had higher comorbidity, Charlson Comorbidity Index 2 or higher, 34% versus 13%, and had lower Pca mortality 12% versus 30%, but similar mortality from other causes. Conclusion: Men with unknown risk category were rare in NPCR but distinctly different from other men in NPCR in many aspects including higher comorbidity and lower Pca mortality.

In the period 2018-2019, 2021, it was estimated that U.S. men aged 65 to 84 years and older had a **** percent chance of developing prostate cancer. This statistic shows the probability of males in the United States developing prostate cancer in 2018-2019, 2021, by age.

The proportion of deaths from prostate cancer (ICD-10 C61) that occur at home. To improve palliative care and service planning for cancer patients in the terminal stages of life, allowing more of them the choice of dying at home. Legacy unique identifier: P00772

According to Cognitive Market Research, The Prostate Cancer Therapeutics Market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future. Europe accounted for a market share of over XX% of the global revenue with a market size of USD XX million. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Prostate Cancer Therapeutics Market held the highest market revenue share in 2024.

Market Dynamics of The Prostate Cancer Therapeutics Market

Key Drivers for The Prostate Cancer Therapeutics Market

Growing Prevalence of Prostate Cancer fuels the Growth of the Prostate Cancer Therapeutics Market

The market for Prostate Cancer therapeutics is anticipated to develop in the future due to the Growing incidence of prostate cancer. According to the National Cancer Institute, the National Institute of Health (The U.S.) depicts that out of roughly 200,000 cases that were reported in 2020, there were 34,000 deaths from prostate cancer, representing a mortality rate of 5.5%. The analysis suggests that 12.1% of men are expected to develop prostate cancer in their lifetime. Thus, the mortality rate increased due to the growing prevalence of prostate cancer. For instance, in January 2024, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, it was estimated that there were about 299,010 new cases of prostate cancer and about 35,250 deaths from prostate cancer. About 1 man in 8 will be diagnosed with prostate cancer during his lifetime. Therefore, the rising incidence of cancer is driving the growth of the prostate cancer drugs market. Source:(https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html) Therefore, the rising prevalence of prostate cancer is propelling the growth of the prostate cancer therapeutics market, highlighting the urgent need for effective treatment options.

Biotechnological innovation in prostate cancer treatment drugs to Drive the Global Market of Prostate Cancer Therapeutics.

The market for prostate cancer medications is significantly influenced by the Biotechnological research and development innovation in prostate cancer treatment drugs. Recent developments in prostate cancer therapies have integrated several bioinformatics and computational biology applications to attain the best possible cancer treatment. Market participants have discovered a successful way to develop new cures and treatments with a targeted approach that includes whole-genome sequencing, exome profiling, and proteome profiling. For instance, Biopep Solutions Inc. is a privately owned development-stage biotechnology company that discovers and develops innovative therapeutic products for the treatment of cancers and other diseases. This Canada-based company focuses its efforts on the development of BPS-001, which is a complex, multivalent biologic drug that possesses anti-tumour attributes. There is a huge demand for innovation in the prostate cancer therapeutics market for products that have enhanced survival time, less toxicity, increased progression-free survival, increased efficacy, and lower cost. Source:(https://www.biopeps.com/bps-001-mechanism-of-action/) Therefore, with a growing population of elderly men worldwide, the demand for prostate cancer therapeutics is expected to soar, emphasizing the importance of tailored medical solutions to address this demographic trend.

Restraint Factor for The Prostate Cancer Therapeutics Market

Recurrent/Non-Responsive Prostate Cancer restrains the growth of the Prostate Cancer Therapeutics market.

The challenge of Recurrent/no...

Rate: Number of deaths due to prostate cancer per 100,000 male population.

Definition: Number of deaths per 100,000 males with malignant neoplasm (cancer) of the prostate as the underlying cause of death (ICD-10 code: C61).

Data Sources:

(1) Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File. CDC WONDER On-line Database accessed at http://wonder.cdc.gov/cmf-icd10.html

(2) Death Certificate Database, Office of Vital Statistics and Registry, New Jersey Department of Health

(3) Population Estimates, State Data Center, New Jersey Department of Labor and Workforce Development

Mortality from prostate cancer (ICD-10 C61 equivalent to ICD-9 185). To reduce deaths from prostate cancer. Legacy unique identifier: P00626

This summary brings together information on prostate cancer incidence, mortality and survival.

Source agency: Office for National Statistics

Designation: National Statistics

Language: English

Alternative title: Prostate cancer: the most common cancer in men in England

A survey from November 2019 to April 2020 of U.S. men with prostate cancer found that around 48 percent sought treatment advice from family or friends, while around 19 percent reported seeking advice from other prostate cancer patients. This statistic illustrates the percentage of men with prostate cancer in the United States who sought treatment advice from select sources as of 2020.

Rate or HR for PSA testing, prostate biopsies, prostate biopsies in men with elevated PSA, and prostatitis diagnosis.

Hazard ratios for the association of different factors with an incident prostate cancer diagnosis.

Numbers are medians (5–95% percentiles) unless otherwise specified1Socioeconomic position of municipalities based on municipality information on education, work market affiliation and incomeBaseline characteristics of the 24,473 male participants in the Diet, Cancer and Health cohort by prostate cancer status.

Years of life lost due to mortality from prostate cancer (ICD-10 C61). Years of life lost (YLL) is a measure of premature mortality. Its primary purpose is to compare the relative importance of different causes of premature death within a particular population and it can therefore be used by health planners to define priorities for the prevention of such deaths. It can also be used to compare the premature mortality experience of different populations for a particular cause of death. The concept of years of life lost is to estimate the length of time a person would have lived had they not died prematurely. By inherently including the age at which the death occurs, rather than just the fact of its occurrence, the calculation is an attempt to better quantify the burden, or impact, on society from the specified cause of mortality. Legacy unique identifier: P00245

BackgroundAmong prostate cancer (PC) patients, over 90% of distant metastases occur in the bone. PC treatments may be associated with side effects, including second primary malignancies (SPM). There is limited information on the incidence of SPM among men with bone metastatic PC (mPC) and among men with bone metastatic castration-resistant PC (mCRPC). We estimated overall survival and the incidence of SPM in men with mPC and mCRPC.MethodsIn the Prostate Cancer data Base Sweden, the National Prostate Cancer Register was linked to other national health care registers, 15,953 men with mPC in 1999–2011 were identified. Further, 693 men with mCRPC were identified. Outcomes were evaluated using stratified incidence rates, Kaplan-Meier estimators and Cox models.ResultsThe mean age among men with mPC was 73.9 years and in men with mCRPC 70.0 years. The median respective survivals were 1.5 (13,965 deaths) and 1.14 years (599 deaths), and average times since PC diagnosis 1.8 and 4.7 years. We observed 2,669 SPMs in men with mPC and 100 SPMs in men with mCRPC. The incidence rate of SPM per 1,000 person-years was 81.8 (78.8–85.0) for mPC and 115.6 (95.1–140.7) for mCRPC. High age, prior neoplasms, urinary tract infection, congestive heart failure, diabetes and renal disease were most strongly associated with increased mortality risk. Prior neoplasms and prior use of antineoplastic agents were most strongly associated with increased SPM risk. Several factors associated with increased mortality and SPM risks were more prevalent in the mCRPC cohort.ConclusionsOur results on mortality for men with mPC and mCRPC are in line with previous studies from the same time period. Investigation of factors associated with mortality and SPM in men with mPC and mCRPC can help to further understand these outcomes in the era prior to several new treatments have come available.

Prostate Specific Antigen (PSA) Test Market Outlook

The Prostate Specific Antigen (PSA) Test market is poised for substantial growth, with the global market size projected to increase from USD 3.2 billion in 2023 to an estimated USD 5.8 billion by 2032, reflecting a robust compound annual growth rate (CAGR) of 6.5% during the forecast period. This growth is fueled by factors such as the increasing prevalence of prostate cancer, rising awareness of cancer screening programs, and technological advancements in diagnostic testing. The PSA test remains one of the most commonly used tools for early detection and monitoring of prostate cancer, which is a significant driver for market expansion.

The primary growth factor for the PSA test market is the increasing prevalence of prostate cancer, which is one of the most common types of cancer among men globally. Prostate cancer's growing incidence has heightened the demand for early detection screenings, making PSA tests crucial. The aging population contributes significantly to this demand, as older men are more susceptible to prostate cancer. Additionally, increased awareness and education about prostate health have led to more men opting for routine screenings. These factors collectively contribute to the rising demand for PSA tests, thereby propelling market growth.

Technological advancements in diagnostic testing have dramatically improved the accuracy and reliability of PSA tests, further bolstering market growth. Innovations such as highly sensitive assays, automated diagnostic platforms, and the development of complexed PSA tests that improve specificity, have enhanced the efficiency of prostate cancer detection. These technological improvements have made PSA testing more accessible and have reduced the number of false-positive results, thus increasing confidence in the tests among healthcare providers and patients alike. This technological progress is also likely to spur additional research and development efforts, further expanding the market.

Another critical factor driving growth in the PSA test market is the increasing support and investment from government and healthcare organizations for cancer screening programs. Many countries have implemented national screening guidelines that recommend regular PSA testing for men over a certain age, often 50 years, or earlier for those with a family history of prostate cancer. These initiatives are designed to reduce cancer mortality rates through early detection and prevention. The implementation of such programs has resulted in a significant rise in the number of PSA tests conducted globally, thereby positively impacting market growth.

From a regional perspective, North America currently holds the largest share of the PSA test market, attributed mainly to a well-established healthcare infrastructure, a high prevalence of prostate cancer, and significant healthcare expenditure. However, the Asia Pacific region is expected to witness the highest growth rate, driven by increasing healthcare awareness, an improving healthcare system, and rising disposable incomes. European countries are also expected to contribute significantly to market growth due to government-supported screening initiatives. The Middle East & Africa and Latin America, though currently having smaller market shares, are anticipated to see steady growth as healthcare infrastructure improves and awareness programs expand.

Test Type Analysis

The PSA test market is segmented into different test types, including Total PSA Test, Free PSA Test, and Complexed PSA Test. The Total PSA Test is the most widely used among these, accounting for the largest market share. This test measures the overall level of prostate-specific antigen in the blood and is a critical tool for initial screening and monitoring of prostate health. The prominence of Total PSA Tests can be attributed to their efficacy in detecting the risk of prostate cancer and their widespread availability in healthcare facilities globally. Efforts to improve the specificity of Total PSA Tests through the development of new assays continue to enhance their market presence.

Free PSA Tests, which measure the proportion of PSA not bound to proteins in the blood, are also gaining traction in the market. These tests are particularly valuable in differentiating prostate cancer from benign prostatic hyperplasia (BPH), a common non-cancerous enlargement of the prostate gland. By providing additional diagnostic information, Free PSA Tests help reduce unnecessary biopsies, which are invasive and costly. The increasing demand for more precise and less invasive

Financial overview and grant giving statistics of Central Ohio Men Against Prostate Cancer

Every year numerous new cases of cancer are diagnosed in Italy. The figure presented refer to the share of specific tumors out of the total number of cancers diagnosed among males in 2020 and in 2022, when the data is available. According to the source, prostate cancer registered the highest incidence among males in 2022, with 19.8 percent, followed by lung tumor, with 15 percent.

Note: RSS = 78237.83; AICc = 10168.14; Adjusted R2 = 0.288995% confidence intervals calculated assuming normally distributed errors: Estimate ± 1.96 × standard error.Coefficient Estimates in the Multivariate Ordinary Least Squares Regression of County Level Prostate Cancer Mortality Rates (per 100,000 men).

Prostate Cancer Diagnostics Market Outlook

The global prostate cancer diagnostics market size was valued at USD 3.5 billion in 2023, and it is projected to reach USD 6.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period. This robust growth is driven by factors such as advancements in diagnostic technologies, increasing awareness about prostate cancer, and the rising prevalence of the disease. With improved healthcare infrastructure and the adoption of novel diagnostic methods, the prostate cancer diagnostics market is primed for significant expansion.

One of the primary growth drivers for the prostate cancer diagnostics market is the increasing prevalence of prostate cancer globally. As the second most common cancer among men, the rising incidence rates have necessitated early and accurate diagnostic methods. Advances in medical technology, including the development of more sensitive and specific biomarkers, have significantly improved the early detection and diagnosis of prostate cancer. Furthermore, initiatives by governments and healthcare organizations to promote regular screening have also contributed to the market's growth.

Technological advancements in diagnostic tools and techniques are another critical factor propelling the market. Innovations such as multiparametric MRI (mpMRI) and advanced biopsy techniques have enhanced the accuracy and reliability of prostate cancer diagnostics. These advancements not only facilitate early detection but also help in staging the cancer, which is crucial for determining the appropriate treatment plan. The integration of artificial intelligence (AI) and machine learning algorithms in diagnostic imaging is further revolutionizing the field by providing more precise interpretations of medical data.

Prostrate Specific Antigen Testing has become a cornerstone in the early detection and management of prostate cancer. This blood test measures the level of PSA in the blood, which can be an indicator of prostate health. Elevated PSA levels may suggest the presence of prostate cancer, prompting further diagnostic evaluations. The test is widely used due to its simplicity and non-invasive nature, making it a preferred choice for initial screening. However, it is important to consider that elevated PSA levels can also be caused by benign conditions such as prostatitis or benign prostatic hyperplasia (BPH). Therefore, PSA testing is often used in conjunction with other diagnostic methods to improve accuracy and reduce the likelihood of false positives.

Additionally, the growing awareness and education about prostate cancer and the importance of early detection have played a significant role in market growth. Public health campaigns and initiatives by various organizations emphasize the need for regular prostate examinations, especially for men over the age of 50. Increased awareness has led to higher rates of screening and early diagnosis, thereby boosting the demand for diagnostic services and products. Moreover, the aging population, which is more susceptible to prostate cancer, is expected to drive the market further.

From a regional perspective, North America holds the largest share of the prostate cancer diagnostics market, attributed to the high prevalence of prostate cancer, advanced healthcare infrastructure, and significant investment in research and development. Europe follows closely, driven by similar factors, along with favorable government policies and initiatives. The Asia Pacific region is expected to witness the highest growth rate, owing to improving healthcare facilities, growing awareness about prostate cancer, and increasing disposable incomes. Latin America and the Middle East & Africa are also projected to experience growth, although at a slower pace, due to the ongoing development of healthcare infrastructure and awareness programs.

Test Type Analysis

The prostate cancer diagnostics market can be segmented by test type into PSA Tests, PCA3 Tests, Biopsy, Imaging, and Others. PSA (Prostate-Specific Antigen) tests are widely used for the initial screening and monitoring of prostate cancer. Despite their widespread use, PSA tests are often criticized for their lack of specificity and potential for false positives, leading to unnecessary biopsies. Nevertheless, ongoing advancements aim to improve the accuracy and reliability of these tests, making them a staple in the diagnostic process.